Development of a soy protein hydrolysate with an antihypertensive effect

International Journal of Molecular Sciences

Volumn 20, Issue 6, 2019, Pages

  Daliri, Eric Banan Mwine ^a   Ofosu, Fred Kwame ^a   Chelliah, Ramachandran ^a   Park, Mi Houn ^b   Kim, Jong Hak ^b   Oh, Deog Hwan ^a  

^a Kangwon National University   (South Korea)

^b Erom Company Limited   (South Korea)

Author keywords

Antihypertensive peptides; Fermentation; Food derived; Functional food

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; LACTIC ACID; PLACEBO; PROTEIN HYDROLYSATE; SOYBEAN PROTEIN; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BACTERIUM CULTURE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT GAIN; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DEVELOPMENT; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; FERMENTATION; HYDROLYSIS; IC50; LACTOBACILLUS RHAMNOSUS; LD50; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN ISOLATION; PROTEIN SYNTHESIS INHIBITION; RAT; REGULATORY MECHANISM; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SYSTOLIC BLOOD PRESSURE; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; ANIMAL; BLOOD PRESSURE; DRUG EFFECT; ENZYMOLOGY; GASTROINTESTINAL TRACT; LEPORIDAE; PIG; SYSTOLE; TIME FACTOR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FERMENTATION; GASTROINTESTINAL TRACT; PROTEIN HYDROLYSATES; RABBITS; SOYBEAN PROTEINS; SWINE; SYSTOLE; TIME FACTORS; WEIGHT GAIN;

EID: 85064210524     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms20061496     Document Type: Article

References (35)

1. Zhou, B.; Bentham, J.; Di Cesare, M.; Bixby, H.; Danaei, G.; Cowan, M.J.; Paciorek, C.J.; Singh, G.; Hajifathalian, K.; Bennett, J.E. Worldwide trends in blood pressure from 1975 to 2015: A pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet 2017, 389, 37–55. [CrossRef]
2. Daliri, E.B.-M.; Lee, B.H.; Park, M.H.; Kim, J.-H.; Oh, D.-H. Novel angiotensin I-converting enzyme inhibitory peptides from soybean protein isolates fermented by Pediococcus pentosaceus SDL1409. LWT 2018, 93, 88–93. [CrossRef]
3. Daliri, E.B.-M.; Lee, B.H.; Oh, D.H. Current trends and perspectives of bioactive peptides. Crit. Rev. Food Sci. Nutr. 2018, 58, 2273–2284. [CrossRef] [PubMed]
4. Ciau-Solís, N.A.; Acevedo-Fernández, J.J.; Betancur-Ancona, D. In vitro renin–angiotensin system inhibition and in vivo antihypertensive activity of peptide fractions from lima bean (Phaseolus lunatus l.). J. Sci. Food Agric. 2018, 98, 781–786. [CrossRef]
5. Bleakley, S.; Hayes, M.; O’Shea, N.; Gallagher, E.; Lafarga, T. Predicted release and analysis of novel ACE-I, renin, and DPP-IV inhibitory peptides from common oat (Avena sativa) protein hydrolysates using in silico analysis. Foods 2017, 6, 108. [CrossRef]
6. Chatterjee, C.; Gleddie, S.; Xiao, C.-W. Soybean bioactive peptides and their functional properties. Nutrients 2018, 10, 1211. [CrossRef]
7. Lin, Q.; Xu, Q.; Bai, J.; Wu, W.; Hong, H.; Wu, J. Transport of soybean protein-derived antihypertensive peptide LSW across Caco-2 monolayers. J. Funct. Foods 2017, 39, 96–102. [CrossRef]
8. Sanjukta, S.; Rai, A.K. Production of bioactive peptides during soybean fermentation and their potential health benefits. Trends Food Sci. Technol. 2016, 50, 1–10. [CrossRef]
9. Nagata, C.; Wada, K.; Tamura, T.; Konishi, K.; Goto, Y.; Koda, S.; Kawachi, T.; Tsuji, M.; Nakamura, K. Dietary soy and natto intake and cardiovascular disease mortality in Japanese adults: The Takayama study. Am. J. Clin. Nutr. 2016, 105, 426–431. [CrossRef]
10. Yan, Z.; Zhang, X.; Li, C.; Jiao, S.; Dong, W. Association between consumption of soy and risk of cardiovascular disease: A meta-analysis of observational studies. Eur. J. Prev. Cardiol. 2017, 24, 735–747. [CrossRef] [PubMed]
11. Vallabha, V.S.; Tiku, P.K. Antihypertensive peptides derived from soy protein by fermentation. Int. J. Pept. Res. Ther. 2014, 20, 161–168. [CrossRef]
12. Thakkar, P.; Patel, A.; Modi, H.; Prajapati, J. Evaluation of antioxidative, proteolytic, and ACE inhibitory activities of potential probiotic lactic acid bacteria isolated from traditional fermented food products. Acta Aliment. 2018, 47, 113–121. [CrossRef]
13. Kumar, R.; Chaudhary, K.; Chauhan, J.S.; Nagpal, G.; Kumar, R.; Sharma, M.; Raghava, G.P. An in silico platform for predicting, screening and designing of antihypertensive peptides. Sci. Rep. 2015, 5, 12512. [CrossRef]
14. Daliri, E.B.-M.; Lee, B.H.; Oh, D.H. Current perspectives on antihypertensive probiotics. Probiot. Antimicrob. Proteins 2017, 9, 91–101. [CrossRef] [PubMed]
15. Ceapa, C.; Davids, M.; Ritari, J.; Lambert, J.; Wels, M.; Douillard, F.P.; Smokvina, T.; de Vos, W.M.; Knol, J.; Kleerebezem, M. The variable regions of Lactobacillus rhamnosus genomes reveal the dynamic evolution of metabolic and host-adaptation repertoires. Genome Biol. Evol. 2016, 8, 1889–1905. [CrossRef]
16. Wijesekara, I.; Kim, S.-K. Angiotensin-i-converting enzyme (ACE) inhibitors from marine resources: Prospects in the pharmaceutical industry. Mar. Drugs 2010, 8, 1080–1093. [CrossRef]
17. Wu, J.; Aluko, R.E.; Nakai, S. Structural requirements of angiotensin I-converting enzyme inhibitory peptides: Quantitative structure− activity relationship study of di-and tripeptides. J. Agric. Food Chem. 2006, 54, 732–738. [CrossRef] [PubMed]
18. Wu, J.; Aluko, R.E.; Nakai, S. Structural requirements of angiotensin I-converting enzyme inhibitory peptides: Quantitative structure-activity relationship modeling of peptides containing 4-10 amino acid residues. QSAR Comb. Sci. 2006, 25, 873–880. [CrossRef]
19. Mourad, J.-J. The evolution of systolic blood pressure as a strong predictor of cardiovascular risk and the effectiveness of fixed-dose arb/ccb combinations in lowering levels of this preferential target. Vasc. Health Risk Manag. 2008, 4, 1315. [CrossRef] [PubMed]
20. Rapsomaniki, E.; Timmis, A.; George, J.; Pujades-Rodriguez, M.; Shah, A.D.; Denaxas, S.; White, I.R.; Caulfield, M.J.; Deanfield, J.E.; Smeeth, L. Blood pressure and incidence of twelve cardiovascular diseases: Lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet 2014, 383, 1899–1911. [CrossRef]
21. Koyama, M.; Hattori, S.; Amano, Y.; Watanabe, M.; Nakamura, K. Blood pressure-lowering peptides from neo-fermented buckwheat sprouts: A new approach to estimating ACE-inhibitory activity. PLoS ONE 2014, 9, e105802. [CrossRef]
22. Wang, S.-K.; Ma, W.; Wang, S.; Yi, X.-R.; Jia, H.-Y.; Xue, F. Obesity and its relationship with hypertension among adults 50 years and older in Jinan, China. PLoS ONE 2014, 9, e114424. [CrossRef]
23. Leggio, M.; Lombardi, M.; Caldarone, E.; Severi, P.; D’Emidio, S.; Armeni, M.; Bravi, V.; Bendini, M.G.; Mazza, A. The relationship between obesity and hypertension: An updated comprehensive overview on vicious twins. Hypertens. Res. 2017, 40, 947. [CrossRef] [PubMed]
24. Nurdiantami, Y.; Watanabe, K.; Tanaka, E.; Pradono, J.; Anme, T. Association of general and central obesity with hypertension. Clin. Nutr. 2018, 37, 1259–1263. [CrossRef]
25. Oh, S.; Shimizu, H.; Satoh, T.; Okada, S.; Adachi, S.; Inoue, K.; Eguchi, H.; Yamamoto, M.; Imaki, T.; Hashimoto, K. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006, 443, 709. [CrossRef] [PubMed]
26. Shimizu, H.; Oh-i, S.; Hashimoto, K.; Nakata, M.; Yamamoto, S.; Yoshida, N.; Eguchi, H.; Kato, I.; Inoue, K.; Satoh, T. Peripheral administration of nesfatin-1 reduces food intake in mice: The leptin-independent mechanism. Endocrinology 2009, 150, 662–671. [CrossRef]
27. Zapata, R.C.; Singh, A.; Chelikani, P.K. Peptide YY mediates the satiety effects of diets enriched with whey protein fractions in male rats. FASEB J. 2017, 32, 850–861. [CrossRef]
28. Yang, H.-Y.; Yang, S.-C.; Chen, J.-R.; Tzeng, Y.-H.; Han, B.-C. Soyabean protein hydrolysate prevents the development of hypertension in spontaneously hypertensive rats. Br. J. Nutr. 2004, 92, 507–512. [CrossRef]
29. Rhyu, M.R.; Kim, E.Y.; Han, J.S. Antihypertensive effect of the soybean paste fermented with the fungus Monascus. Int. J. Food Sci. Technol. 2002, 37, 585–588. [CrossRef]
30. Wu, J.; Ding, X. Hypotensive and physiological effect of angiotensin converting enzyme inhibitory peptides derived from soy protein on spontaneously hypertensive rats. J. Agric. Food Chem. 2001, 49, 501–506. [CrossRef] [PubMed]
31. Barnes, V.A.; Orme-Johnson, D.W. Prevention and treatment of cardiovascular disease in adolescents and adults through the transcendental meditation®program: A research review update. Curr. Hypertens. Rev. 2012, 8, 227–242. [CrossRef] [PubMed]
32. Daliri E. Kangwon National University, Chuncheon-si, Korea. 2015.
33. García-Tejedor, A.; Padilla, B.; Salom, J.B.; Belloch, C.; Manzanares, P. Dairy yeasts produce milk protein-derived antihypertensive hydrolysates. Food Res. Int. 2013, 53, 203–208. [CrossRef]
34. Cushman, D.W.; Cheung, H.S. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem. Pharmacol 1971, 7, 1637–1648. [CrossRef]
35. Chang, O.K.; Roux, É.; Awussi, A.A.; Miclo, L.; Jardin, J.; Jameh, N.; Dary, A.; Humbert, G.; Perrin, C. Use of a free form of the Streptococcus thermophilus cell envelope protease prts as a tool to produce bioactive peptides. Int. Dairy J. 2014, 38, 104–115. [CrossRef]